Dec 29, 2008 - Salix Pharmaceuticals, Ltd. today announced that the Company has received a complete response letter from the U.S. Food and Drug Administration for its New Drug Application for balsalazide tablet studied as a treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.
The details can be read here.
No comments:
Post a Comment